Monte Rosa Therapeutics develops molecular glue degrader medicines for serious diseases using its QuEEN discovery engine, which combines AI-guided chemistry, chemical libraries, structural biology and proteomics. The company’s news centers on clinical and preclinical updates for programs including MRT-8102, a NEK7-directed degrader for inflammatory disease biology; MRT-2359, a GSPT1-directed degrader studied in metastatic castration-resistant prostate cancer; and MRT-6160, a VAV1-directed degrader for immune-mediated diseases.
Recurring developments also include oncology discovery work such as cyclin E1-directed and CDK2-directed degrader programs, clinical supply and pharmaceutical collaboration activity, quarterly financial results, equity awards, capital resources and public-company governance updates.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Monte Rosa Therapeutics has announced its second development candidate, MRT-6160, a novel molecular glue degrader (MGD) targeting VAV1 for the treatment of autoimmune diseases. The company plans to file an Investigational New Drug (IND) application for MRT-6160 in the first half of 2024.
Preclinical data show that MRT-6160 potently and selectively degrades VAV1, inhibiting disease progression in autoimmunity models. The molecule acts as an immune modulator, potentially avoiding broad immune suppression seen with other approaches. MRT-6160 is designed to attenuate multiple aspects of T- and B-cell function.
Monte Rosa (Nasdaq: GLUE) aims to develop MRT-6160 as a potential treatment for various autoimmune conditions, particularly those involving T- and B cell-mediated autoimmunity. The company expects it to be their second MGD to enter clinical trials, highlighting the productivity of their QuEEN™ platform.